Find research datasets worth reusing

opencc-by-4.0Jan 2020View details →

Data from Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta‐analysis of controlled studies

This dataset contains three text files in RIS format. They represent the screening process during study selection for "Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta‐analysis of controlled studies" (<a href="https://doi.org/10.1111/liv.14179">https://doi.org/10.1111/liv.14179</a>). The file DOKU_All TiAb-Screening_20200116_cap contains all 3453 records (merged from original and update search) that were subjected to title-abstract screening. The file DOKU_All FT-Screening_20200116_cap contains all 174 records that were subjected to full-text screening. The file DOKU_All Included_20200116_cap contains all 26 records that were included into the final review. In addition, a PRISMA flow diagram (Fig. 1 in the paper) is available in TIF format.

opencc-by-4.0Apr 2022View details →

Development of a machine learning model to predict non- durable response to anti-TNF therapy in Crohn's disease using transcriptome imputed from genotypes

This is the expression value predicted using PrediXcan version 7 to find a gene feature that can distinguish between patients with and without effect on infliximab. Among the various tissue models provided by PrediXcan v7, three models were selected and used: whole blood, Colon transverse, and terminal ileum of small intestine, and the predicted gene counts of each model were 6,294, 5,612 and 3,107. For each of the three models, predicted gene expression values and phenotype information per sample were submitted.

Figure 4. (a) Therapy player software screen, where a) is the stimuli time, b) is the total therapy time, c) is the file path, d) displays the numeric values of each sequence of the therapy, e) shows the current value, and f) shows the current lag angle for zenith and azimuth values; (b) USB mechanism for conversion, where a) USB-UART converter, and b) USB-Zigbee converter.-Design of a Novel Servo-motorized Laser Device for Visual Pathways Diseases Therapy

Where tt time expended by the servomotors to point the laser to a given position and execute a laser beam sequence; tspin is the time that a servomotor needs to spin one degree; ttol is a given the tolerance time; θservo is the addition of degrees that both servos in a laser driver need to spin point the laser in a given position; tstimuli is the time expended in execute a laser beam, between 250 and 605 ms (Weiskrantz et al., 1991); T is the total time of all repetitions in a therapy, suggested between 20 and 60 minutes and N is the number of repetitions in a therapy.

Figure 3. (Top): Illustration of the therapy selection main menu. This enables the user to select one of three options for the therapy. Stimuli sequence selectors; (Bottom): (a) Short distance – complete visual field; (b) Short distance – macular; (c) Middle-long distance.-Design of a Novel Servo-motorized Laser Device for Visual Pathways Diseases Therapy

distance therapies for the prescribed time suggested by the ophthalmologist. Note that the complete visual field therapy stimulates different parts in the entire visual field whereas macular therapy stimulate only a small part of the visual field, only the first 10° of vision range. In contrast, middle-long distance therapies are not developed inside the device; instead the patient must sit watching a wall, where the stimuli will be presented. Figure 3 (Bottom) shows the sequence selectors for the three different cases. The therapist will choose a desired number of sequences according to the results of the examination to each patient; hence it is completely patient dependent. Once the therapist finishes the particular design of the stimuli sequence, the software automatically displays a window where he can save the customized patient-specific details for future use as a text file.

Figure 2. (a) Representation of laser servo-driver for inverse kinematics analysis; (b) Representation of the lag angle, B, of the internal servomechanism (magnified version of the chin-rest).-Design of a Novel Servo-motorized Laser Device for Visual Pathways Diseases Therapy

As the servo-driver will be attached in the chin-rest in a non-central area with respect to the semispherical structure shown in Figure 1(a), it is necessary to calculate a lag angle, according to the measurements from the chin-rest, see Figure 2(b). This was done using a hybrid formula based on the law of cosines,

Figure 1. (a) Part of the acrylic structure where the patient is enclosed to avoid external stimulus; (b) Chin rest, corresponding proportions and measurements.-Design of a Novel Servo-motorized Laser Device for Visual Pathways Diseases Therapy

The device consists mainly of an acrylic semi-spherical structure (Figure 1(a)) where visual stimuli will be shown, according to a pre-designed therapy. Four servomotors will drive the lasers, two inside the structure (short distances drive the lasers, two inside the structure (short distance therapies) and two outside (middle-long distance therapies). A chin-rest must be used to have a better line of sight fixation. A webcam with infrared light will catch the Purkinje-Sanson images to identify the sight line (Borah, 2006; Halswanter, 2011; Pambakian et al., 2000). LabVIEW software is used to control the device, including an audio stimulus along with an image-processing pipeline. Finally a microcontroller is used to control the servo movements, laser beams and buzzers.

opencc-by-4.0Aug 2023View details →

A more accurate risk biomarkers recognition for Progressive Multifocal Leukoencephalopathy (PML) caused by Polyomavirus JC in patients with multiple sclerosis during treatment with disease-modifying therapies (DMTs): an ongoing clinical challenge.

The therapeutic scenario for the treatment of MS has recently been characterized by a veritable revolution, which has included the introduction, for the first time, of drug treatment guidelines and the entry, in the therapeutic landscape of the last decade, of numerous new drugs that, in varying but significantly relevant ways, have proven capable of modifying the course of the disease (Disease-Modifying Therapies - DMTs).  While the arsenal of available drugs has resulted in advances in efficacy and selectivity, it has also exposed them to the danger of side effects, potentially serious and in some cases even fatal. Among the most important side effects, complications of infectious origin, characterized by cases of viral infection/reactivation, as in the case of JCPyV, the etiologic agent of PML, are the most represented. This study, based on the follow-up of MS patients treated with different DMTs, contributes to implementing the data in the literature regarding a greater understanding of the risks related to the administration of these drugs and more appropriate monitoring of MS treatment. The risk of JCPyV reactivation with Fingolimod and Dimethyl fumarate is lower than the risk of viral reactivation associated with natalizumab. In light of the data obtained, it is possible to conclude that, in the case of natalizumab, testing for JC viruria would seem to be more useful in identifying those patients with a JCPyV-specific humoral response that is not yet detectable. In addition, our results, draw attention to the importance of analyzing the NCCR rearrangements of JCPyV. Indeed, the particular rearrangements found in plasma and PBMCs of patients with RRMS treated with natalizumab could represent an alert of neuroinvasiveness in order to detect early those patients with a higher risk of developing PML. In the case of dimethyl fumarate, it seems likely that monitoring of lymphopenia would identify a higher risk group of patients in whom alternative therapy should be sought. Prolonged lymphopenia, with absolute lymphocyte counts less than 750 lymphocytes/mL, might be the major risk factor for PML although, a greater risk might lie in the loss of CD8+ cells that are crucial for JCPyV control. For fingolimod, this strategy cannot be applied because the number of circulating lymphocytes decreases while the actual lymphocyte function appears largely normal therefore, monitoring viruria and viremia along with identification of the neurotrophic variant of the virus seems a more exploitable means for risk stratification. In conclusion, the results of this study can be considered directly transferable to the National Health System in that, both the monitoring of JCPyV reactivation by viruria and the sequence analysis of viral NCCR and host immune set-up could play the role of translatable biomarkers in clinical practice in order to assess the risk of PML onset. In addition to improving risk stratification of this disease, these biomarkers of viral reactivation and pathogenicity could facilitate timely diagnosis, optimizing the use of health care resources and contributing to the reduction of direct and indirect costs of MS disease. Prezioso Carla was supported by the Italian Ministry of Health (Starting Grant: SG-2018-12366194).

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

ClinicalTrials.gov study NCT03345836. IPD Sharing: YES. Countries: 48. Publications: 7.

Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have No

ClinicalTrials.gov study NCT02782741. IPD Sharing: YES. Countries: 25. Publications: 4.

Triple Combination Therapy in High Risk Crohn's Disease (CD)

ClinicalTrials.gov study NCT02764762. IPD Sharing: YES. Countries: 2. Publications: 1.

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

ClinicalTrials.gov study NCT03623243. IPD Sharing: YES. Countries: 2. Publications: 1.

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

ClinicalTrials.gov study NCT03149809. IPD Sharing: YES. Countries: 1. Publications: 1.

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

ClinicalTrials.gov study NCT01895361. IPD Sharing: YES. Countries: 3. Publications: 3.

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

ClinicalTrials.gov study NCT02913261. IPD Sharing: YES. Countries: 22. Publications: 5.

Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

ClinicalTrials.gov study NCT04186247. IPD Sharing: YES. Countries: 4. Publications: 1.

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

ClinicalTrials.gov study NCT02611817. IPD Sharing: YES. Countries: 30. Publications: 1.